Prostate Cancer

New Study Shows HIFU for Prostate Cancer Yields Excellent Cancer Control

New 5-Year Sonablate® Study Shows Focal HIFU for Prostate Cancer Yields Excellent Cancer Control with Minimal Side Effects HIFU Prostate Services, the largest provider of HIFU Services in US is pleased to announce an Extensive Multicenter Research Study that Demonstrates Sonablate® HIFU Outcomes are Equivalent to Surgery While Maintaining Urinary Continence and Erectile Function Charlotte, N.C. (July 6, 2018) – A 5-year multicenter study following focal therapy for prostate cancer, with the Sonablate HIFU technology, has been published and shows it is possible to achieve whole-gland equivalent cancer control rates without the side effects seen with whole gland treatments. The data demonstrated that focal Sonablate HIFU, or High Intensity Focused Ultrasound, has achieved success rates similar to more traditional prostate cancer surgical procedures [...]

2018-07-17T10:08:41+00:00July 17th, 2018|

Global health insurance company Cigna covers HIFU

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center --> Cigna, a a global health insurance service company based in the US, announced earlier this year that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage for HIFU treatment. In other words, if a man was diagnosed with localized prostate cancer and then had radiation therapy then had the cancer return to the prostate and was diagnosed with localized recurrent prostate cancer, he may be eligible for coverage for having HIFU as a salvage option. It is important to note that coverage is policy specific so it may vary depending on the policy.  More information is available from Cigna [...]

2018-06-19T14:59:20+00:00June 19th, 2018|

It’s Men’s Health Month – A Focus on Prostate Cancer Prevention

Is prostate cancer prevention possible? Urologist and prostate cancer specialist Dr. Michael Lazar talks about prevention and options for maintaining health after a cancer diagnosis. June is Men’s Health Month and the focus is on prostate cancer. Second only to skin cancer, prostate cancer is the most common cancer among men in the U.S. and the third most common cause of cancer related death today; lung cancer remains in the number one spot. Currently it is estimated that one man in seven will be diagnosed with prostate cancer during his lifetime. Those at highest risk are men who have a family history of prostate cancer and black men, who are more than twice as likely to die from the disease as any other group. [...]

2018-06-12T07:40:41+00:00June 12th, 2018|

New study reviews PSA screening results following prostate cancer treatment

A study assessed whether monitoring prostate cancer patients following treatment with a PSA test every three months versus once a year would provide a long-term survival benefit. Prostate cancer patients who were monitored more frequently after treatment did not live significantly longer than patients who were monitored once a year, according to study findings led by a University of North Carolina Lineberger Comprehensive Cancer Center researcher. At the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, researchers presented findings on Friday, June 1, from an analysis of data from nearly 10,500 prostate cancer patients in the United States from 2005 to 2010. The study's primary goal was to determine if more frequent monitoring with the prostate-specific antigen test after treatment improved patients' [...]

2018-06-05T11:03:37+00:00June 5th, 2018|

New biopsy technology may identify better course of treatment for prostate cancer

Prostate cancer is the second most common cancer in men and the fifth leading cause of death from cancer in men worldwide, according to 2012 numbers. While several viable treatment options for prostate cancer exist, many men affected with prostate cancer will not respond to first-line treatments. Researchers in the Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto have developed a new technology for liquid biopsy to identify which patients may not respond to standard therapy before it is delivered. "Screening for drug resistance is key to improving treatment approaches for many cancers," said Shana Kelley, scientist and professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. "It's important for patients not to be on a [...]

2018-04-24T10:27:34+00:00April 24th, 2018|

Wives of many prostate cancer sufferers challenged by the disease

Many wives of advanced prostate cancer sufferers feel that their lives are being undermined by their husband’s illness, with nearly half reporting that their own health suffered. In addition a focus subgroup has revealed that many feel isolated and fearful, and worry about the role change in their lives as their husband’s cancer advances. This study, developed with the wives of men with metastatic prostate cancer who were being treated with hormone therapy, is amongst the first carried out on how prostate cancer affects the partners of sufferers. It was presented yesterday at the EAU conference in Copenhagen. Prostate cancer is the most common male cancer. Prostate cancer which metastisises to other parts of the body is often difficult or impossible to cure, and [...]

2018-03-27T16:53:05+00:00March 27th, 2018|

Random PSA screening misses some aggressive and lethal prostate cancers

UK researchers say that inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives. This from the largest ever prostate cancer trial conducted over 10 years by Cancer Research UK-funded scientists and published in the Journal of the American Medical Association (JAMA). Researchers at the Universities of Bristol and Oxford found that testing asymptomatic men with PSA detects some disease that would be unlikely to cause any harm but also misses some aggressive and lethal prostate cancers. This highlights the flaws of a single PSA test as a way to screen for prostate cancer, and shows the need to find more accurate ways to diagnose cancers that need to be treated. The CAP Trial, which spanned almost [...]

2018-03-13T10:59:50+00:00March 13th, 2018|

New PET scan targets copper in tumors to detect prostate cancer

An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level). Copper tends to be more concentrated in tumors, making it a good imaging biomarker. For this study of 50 patients, researchers conducted PET/CT scans comparing the new imaging agent, copper-64 chloride (64CuCl2), with fluorine-18-choline (18F-Choline). Multiparametric magnetic resonance imaging (mpMRI) was also conducted. In addition to calculating the detection rate of each imaging modality, the biodistribution, kinetics of the lesions and radiation dosimetry of 64CuCl2 were evaluated. "This is the first time this novel agent has been compared with 18F-Choline-PET/CT in a considerable number of prostate [...]

2018-03-06T07:35:43+00:00March 6th, 2018|

Blocking prostate cancer cells metabolism with drug therapy may inhibit growth

For years, attempts have been made to understand the mechanism behind the proliferation of cancer cells: they need metabolites to grow and proliferate as much as a vehicle needs gasoline or electricity to move. However, until now it was not known which metabolites cancer cells actually need. A team of researchers from the Institute of Oncology Research (IOR) at the Università della Svizzera Italiana (USI, Faculty of Biomedical Sciences) led by Prof. Andrea Alimonti has identified one of the mechanisms behind this process, as published in a recent article in the journal Nature Genetics. From a theory dating back to the early 20th century by Nobel Prize laureate Otto Warburg, it has been believed that, in order to support their growth, cancer cells needed [...]

2018-02-13T09:06:03+00:00February 13th, 2018|

Cancerous tissue discernible from healthy tissue in prostate cancer patients

Using nuclear medicine, researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research demonstrates that the maximum standardized uptake value (SUVmax) on 68Ga-PSMA PET/CT scans correlates with PSMA-expression in primary prostate cancer. By this means, researchers were able to generate an SUVmax cutoff for the differentiation of cancerous and benign prostate tissue. Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine. According to the American Cancer Society, one in nine men will be diagnosed with prostate cancer in his lifetime. Early diagnosis is key to successful treatment. The new [...]

2018-02-06T08:27:54+00:00February 6th, 2018|